Ultragenyx Acquires Global Rights to AAV Gene Therapy ...
Ultragenyx acquires global rights to ABO-102, a gene therapy for Sanfilippo Syndrome Type A, from Abeona Therapeutics. Interim data from the Transpher A trial shows potential in preserving neurocognitive development in treated children. Ultragenyx to lead the program, with Abeona eligible for royalties and milestone payments.
Related Clinical Trials
Reference News
Ultragenyx Acquires Global Rights to AAV Gene Therapy ...
Ultragenyx acquires global rights to ABO-102, a gene therapy for Sanfilippo Syndrome Type A, from Abeona Therapeutics. Interim data from the Transpher A trial shows potential in preserving neurocognitive development in treated children. Ultragenyx to lead the program, with Abeona eligible for royalties and milestone payments.